The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning
NCT ID: NCT04957407
Last Updated: 2021-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2019-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Optimal Surveillance Frequency for Stage II/III Gastric Cancer
NCT05465993
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427
The Efficacy of Precision Treatment for Gastric Cancer Guided by Molecular Profiling
NCT04501887
Predicting Biomarker of Gastric Cancer Chemotherapy Response
NCT03253107
Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
NCT05812287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-atrophic gastritis
OLGA-0 group;OLGA (Operative Link on Gastritis Assessment)
No interventions assigned to this group
mild-moderate atrophic gastritis
OLGA I-II group;OLGA (Operative Link on Gastritis Assessment)
No interventions assigned to this group
severe atrophic gastritis
OLGA III-IV group;OLGA (Operative Link on Gastritis Assessment)
pepsinogen
diagnostic value of pepsinogen for severe atrophy and gastric cancer
gastric cancer
gastric cancer
pepsinogen
diagnostic value of pepsinogen for severe atrophy and gastric cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pepsinogen
diagnostic value of pepsinogen for severe atrophy and gastric cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
25 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuling Tong, Dr.
Role: PRINCIPAL_INVESTIGATOR
2nd affiliated hospital of Zhejiang University, school of medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Hangzhou, , China
Ningbo cadres health center
Ningbo, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Yi Zhao, Master
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xuan Huang
Role: primary
Tong Huang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
71804161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.